Supporting Innovation in Early-Stage Pharmaceutical Development Decisions

References

• Ackermann F, Franco LA, Rouwette E, White L (2014) Special issue on problem structuring research and practice. EURO J. Decision Processes 2(3–4):165–172.Crossref, Google Scholar
• Angelis A, Kanavos P, Montibeller G (2017) Resource allocation and priority setting in healthcare: A multi-criteria decision analysis problem of value? Global Policy 8(S2):76–83.Crossref, Google Scholar
• Angelis A, Linch M, Montibeller G, Molina-Lopez T, Zawada A, Orzel K, Arickx F, Espin J, Kanavos P (2020a) Multiple criteria decision analysis for HTA across four EU member states: Piloting the advance value framework. Soc. Sci. Medicine 246:112595.Crossref, Google Scholar
• Angelis A, Thursz M, Ratziu V, O’Brien A, Serfaty L, Canbay A, Schiefke I, Bana e Costa J, Lecomte P, Kanavos P (2020b) Early health technology assessment during nonalcoholic steatohepatitis drug development: A two-round, cross-country, multicriteria decision analysis. Medical Decision Making 40(6):830–845.Crossref, Google Scholar
• Bana e Costa CA, Ensslin L, Cornea EC, Vansnick JC (1999) Decision support systems in action: Integrated application in a multicriteria decision aid process. Eur. J. Oper. Res. 113(2):315–335.Crossref, Google Scholar
• Bayer AG (2020) Annual Report 2019 (Bayer AG, Leverkusen, Germany).Google Scholar
• Bayer Pharmaceuticals (2019) Accessed October 30, 2019, https://pharma.bayer.com/development-pipeline.Google Scholar
• Belton V, Ackermann F, Shepherd I (1997) Integrated support from problem structuring through to alternative evaluation using COPE and V.I.S.A. J. Multi-Criteria Decision Anal. 6(3):115–130.Crossref, Google Scholar
• Bode-Greuel KM, Nickisch KJ (2008) Value-driven project and portfolio management in the pharmaceutical industry. J. Commercial Biotechnology 14:307–325.Crossref, Google Scholar
• Buede DM (1986) Structuring value attributes. Interfaces 16(2):52–62.Link, Google Scholar
• Bunnage ME (2011) Getting pharmaceutical R&D back on target. Nature Chemical Biology 7:335–339.Crossref, Google Scholar
• Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN (2014) Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework. Nature Rev. Drug Discovery 13:419–431.Crossref, Google Scholar
• Delbecq AL, Van de Ven AH, Gustafson DH (1975) Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes (Scott, Foresman).Google Scholar
• Ding M, Dong S, Eliashberg J, Gopalakrishnan A (2013) Portfolio management in new drug development. Innovation and Marketing in the Pharmaceutical Industry (Springer, New York).Google Scholar
• Dyer JS, Sarin RK (1979) Measurable multiattribute value functions. Oper. Res. 27(4):810–822.Link, Google Scholar
• Eden C (1988) Cognitive mapping. Eur. J. Oper. Res. 36(1):1–13.Crossref, Google Scholar
• Fishburn PC, Keeney RL (1974) Seven independence concepts and continuous multiattribute utility functions. J. Math. Psych. 11(3):294–327.Crossref, Google Scholar
• Franco LA, Montibeller G (2010a) Facilitated modelling in operational research. Eur. J. Oper. Res. 205(3):489–500.Crossref, Google Scholar
• Franco LA, Montibeller G (2010b) Problem structuring for multicriteria decision analysis interventions. Wiley Encyclopedia of Operations Research and Management Science.Google Scholar
• Hartmann M, Hassan A (2006) Application of real options analysis for pharmaceutical R&D project valuation—Empirical results from a survey. Res. Policy 35(3):343–354.Crossref, Google Scholar
• Höfer T, von Nitzsch R, Madlener R (2020) Using value-focused thinking and multicriteria decision making to evaluate energy transition alternatives. Decision Anal. 17(4):330–355.Link, Google Scholar
• Howard R (1988) Decision analysis: Practice and promise. Management Sci. 34(6):679–695.Link, Google Scholar
• Ijzerman M, Steuten L (2011) Early assessment of medical technologies to inform product development and market access: A review of methods and applications. Appl. Health Econom. Health Policy 9(5):331–347.Crossref, Google Scholar
• Ijzerman M, Koffijberg H, Fenwick E, Krahn M (2017) Emerging use of early health technology assessment in medical product development: A scoping review of the literature. PharmacoEconomics 35(7):727–740.Crossref, Google Scholar
• Kaitin K (2010) Deconstructing the drug development process: The new face of innovation. Clinical Pharmacology Therapeutics 87(3):356–361.Crossref, Google Scholar
• Keeney RL (1994a) Creativity in decision making with value-focused thinking. Sloan Management Rev. 35(4):33–41.Google Scholar
• Keeney RL (1994b) Using values in operations research. Oper. Res. 42(5):793–813.Link, Google Scholar
• Keeney RL (1996) Value-Focused Thinking (Harvard University Press, Cambridge, MA).Crossref, Google Scholar
• Keeney RL (2002) Common mistakes in making value trade-offs. Oper. Res. 50(6):935–945.Link, Google Scholar
• Keeney RL, Raiffa H (1993) Decisions with Multiple Objectives: Preferences and Value Trade-offs (Cambridge University Press, Cambridge, UK).Crossref, Google Scholar
• Keeney RL, von Winterfeldt D (2007) Practical value models. Edwards W, Miles R, von Winterfeldt D, eds. Advances in Decision Analysis: From Foundations to Applications (Cambridge University Press, Cambridge, UK).Crossref, Google Scholar
• Kleinmuntz D (2007) Resource allocation decisions. Edwards W, Miles R, von Winterfeldt D, eds. Advances in Decision Analysis: From Foundations to Applications (Cambridge University Press, Cambridge, UK).Crossref, Google Scholar
• Lakdawalla D, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM (2018) Defining elements of value in healthcare—A health economics approach: An ISPOR special task force report. Value Health 21(2):131–139.Crossref, Google Scholar
• Lexchin J (2020) Development time and patent extension for prescription drugs in Canada: A cohort study. Internat. J. Health Policy Management 10(8):495–499.Google Scholar
• Marsh K, Ijzerman M, Thokala P, Baltussen R, Boysen M, Kaló Z, Lönngren T, et al. (2016) Multiple criteria decision analysis for healthcare decision making—Emerging good practices: Report 2 of the ISPOR MCDA emerging good practices task force. Value Health 19(2):125–137.Crossref, Google Scholar
• Montibeller G, von Winterfeldt D (2015) Cognitive and motivational biases in decision and risk analysis. Risk Anal. 35(7):1230–1251.Crossref, Google Scholar
• Montibeller G, Patel P, Del Rio Vilas VJ (2020) A critical analysis of multi-criteria models for the prioritisation of health threats. Eur. J. Oper. Res. 281(1):87–99.Crossref, Google Scholar
• Montibeller G, Franco LA, Lord E, Iglesias A (2009) Structuring resource allocation decisions: A framework for building multi-criteria portfolio models with area-grouped options. Eur. J. Oper. Res. 199(3):846–856.Crossref, Google Scholar
• Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, et al. (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Rev. Drug Discovery 17:167–181.Crossref, Google Scholar
• Owens PK, Raddad E, Miller JW, Stille JR, Olovich KG, Smith NV, Jones RS, Scherer JC (2015) A decade of innovation in pharmaceutical R&D the chorus model. Nature Rev. Drug Discovery 14:17–28Crossref, Google Scholar
• Parnell GS, Miller WD (2016) Identifying objectives and value measures. Parnell GS, ed. Trade-off Analytics: Creating and Exploring the System Tradespace (John Wiley & Sons).Google Scholar
• Parnell GS, Bresnick TA, Johnson ER (2013) Craft the decision objectives and value measures. Handbook of Decision Analysis (John Wiley & Sons, Hoboken, NJ).Crossref, Google Scholar
• Phillips L (2007) Decision conferencing. Edwards W, Miles R, von Winterfeldt D, eds. Advances in Decision Analysis: From Foundations to Applications (Cambridge University Press, Cambridge, UK).Crossref, Google Scholar
• Phillips LD, Bana e Costa CA (2007) Transparent prioritisation, budgeting and resource allocation with multi-criteria decision analysis and decision conferencing. Ann. Oper. Res. 154(1):51–68.Crossref, Google Scholar
• Plenge RM (2016) Disciplined approach to drug discovery and early development. Sci. Translational Medicine 8(349):349ps15.Crossref, Google Scholar
• Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nature Rev. Drug Discovery 11:191–200.Crossref, Google Scholar
• Schuhmacher A, Gassmann O, Hinder M (2016) Changing R&D models in research based pharmaceutical companies. J. Translational Medicine 14(105).Google Scholar
• Seidler M, Van der Meer R, Karelis P (2019) R&D Productivity: An Issue of Bad Decision Making (Strategic Decisions Group).Google Scholar
• Seifert R (2019) Basic Knowledge of Pharmacology (Springer International Publishing, Basel).Crossref, Google Scholar
• Siebert JU (2016) Can novices create alternatives of the same quality as experts. Decision Anal. 13(4):278–291.Link, Google Scholar
• Siebert JU, Keeney RL (2015) Creating more and better alternatives for decisions using objectives. Oper. Res. 63(5):1144–1158.Link, Google Scholar
• Siebert JU, von Winterfeldt D (2020) Comparative analysis of terrorists’ objectives hierarchies. Decision Anal. 17(2):97–114.Link, Google Scholar
• Siebert JU, Brandenburg M, Siebert J (2020) Defining and aligning supply chain objectives before, during, and after the COVID-19 pandemic. IEEE Engrg. Management Rev. 48(4):72–85.Crossref, Google Scholar
• Siebert JU, von Winterfeldt D, John RS (2017) Identifying and structuring the objectives of the Islamic State of Iraq and the Levant (ISIL) and its followers. Decision Anal. 13(1):26–50.Link, Google Scholar
• Smietana K, Ekstrom L, Jeffery B, Moller M (2015) Improving R&D productivity. Nature Rev. Drug Discovery 14:455–456.Crossref, Google Scholar
• Smith JE, Dyer JS (2021) On (measurable) multiattribute value functions: An expository argument. Decision Anal. 18(4):247–256.Link, Google Scholar
• Spetzler C, Winter H, Meyer J (2016) Decision Quality: Value Creation from Better Business Decisions (John Wiley & Sons, Hoboken, NJ).Crossref, Google Scholar
• Steven SE (2002) Focused portfolio measures to support decision making throughout the pipeline. Drug Inform. J. 36(3):623–630.Crossref, Google Scholar
• Stewart JJ, Allison PN, Johnson RS (2001) Putting a price on biotechnology. Nature Biotechnology 19:813–817.Crossref, Google Scholar
• Stonebraker JS (2002) How Bayer makes decisions to develop new drugs. Interfaces 32(6):77–90.Link, Google Scholar
• Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T, Mussen F, et al. (2016) Multiple criteria decision analysis for healthcare decision making—An introduction: Report 1 of the ISPOR MCDA emerging good practices task force. Value Health 19(1):1–13.Crossref, Google Scholar
• Tiggemann RF, Dworaczyk DA, Sabel H (1998) Project portfolio management: A powerful strategic weapon in pharmaceutical drug development. Drug Inform. J. 32(3):813–824.Crossref, Google Scholar
• U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE) Version 5.0. Accessed March 9, 2022, https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.Google Scholar
• Vennemann M, Ruland V, Kruse JP, Harloff C, Trübel H, Gielen-Haertwig et al. (2019) Future unmet medical need as a guiding principle for pharmaceutical R&D. Drug Discovery Today 24(9)1924–1929.Crossref, Google Scholar
• von Nitzsch R, Weber M (1993) The effect of attribute ranges on weights in multiattribute utility measurements. Management Sci. 39(8):937–943.Link, Google Scholar
• von Nitzsch R, Tönsfeuerborn M, Siebert J (2020) Decision skill training with the Entscheidungsnavi. Innovation for Systems Information and Decision Meeting (Springer, Cham, Switzerland).Google Scholar
• von Winterfeldt D, Edwards W (1986) Decision Analysis and Behavioral Research (Cambridge University Press, Cambridge, UK).Google Scholar